X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/gsk-details-blenrep-combo-data-could-bring-multiple-myeloma-adc-back-life
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-says-blood-cancer-drug-meets-primary-goal-late-stage-trial-2023-11-27/
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-plus-bortezomib-and-dexamethasone-included-for-reimbursement-by-the-pbs-in-australia-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma-301839510.html
https://www.onclive.com/view/mhra-approves-selinexor-plus-bortezomib-dexamethasone-for-multiple-myeloma-following-1-prior-therapy
https://www.prnewswire.com/news-releases/karyopharm-and-menarini-group-receive-full-marketing-authorization-from-the-uk-medicines--healthcare-products-regulatory-agency-for-nexpovio-selinexor-in-combination-with-bortezomib-and-dexamethasone-for-the-treatment-of-adult-301751848.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205160
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211898
https://www.clinicaltrialsarena.com/news/janssen-trial-multiple-myeloma/
https://www.pharmatimes.com/news/smc_approve_johnson_and_johnsons_systemic_light_chain_amyloidosis_therapy_1453205
http://www.pharmafile.com/news/721160/smc-accepts-first-licensed-treatment-newly-diagnosed-al-amyloidosis
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202963
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203654
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204405
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208460
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208460
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212958
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215011
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gland-pharma-launches-generic-cancer-treatment-drug-in-us/articleshow/91313253.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205533
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209659
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210824
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212825
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213823
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-gets-usfdas-nod-to-market-generic-version-of-bortezomib/articleshow/91283848.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203654
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208460
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-approved-by-the-tga-in-australia-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma-and-triple-class-refractory-multiple-myeloma-301498919.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-02-2022-1646291076.pdf
https://endpts.com/troubled-cancer-center-in-connecticut-handed-form-483-by-fda-again/
http://www.pharmafile.com/news/600992/nice-recommends-combination-treatment-patients-multiple-myeloma
https://www.fiercebiotech.com/biotech/takeda-s-early-stage-multiple-myeloma-treatment-leads-to-response-38-patients
https://www.clinicaltrialsarena.com/news/icr-drugs-bone-marrow-cancer/
https://www.fiercepharma.com/pharma/sanofi-johnson-johnson-collision-course-sarclisa-darzalex-4-drug-multiple-myeloma
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209659
https://www.globenewswire.com/news-release/2021/06/22/2251169/0/en/Genmab-Announces-that-Janssen-has-Received-European-Marketing-Authorizations-for-DARZALEX-daratumumab-Subcutaneous-Formulation-Including-for-the-Treatment-of-Patients-with-Newly-Di.html
https://www.biospace.com/article/releases/janssen-submits-application-seeking-u-s-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-the-treatment-of-patients-with-light-chain-al-amyloidosis/#:~:text=Companies%20of%20Johnson%20%26%20Johnson%20announced,the%20treatment%20of%20patients%20with
https://www.prnewswire.com/news-releases/eha25virtual-study-of-subcutaneous-daratumumab-shows-improved-clinical-outcomes-in-the-treatment-of-patients-with-amyloidosis-301075077.html
https://www.globenewswire.com/news-release/2020/05/28/2040538/0/en/Karyopharm-Reports-Positive-Phase-3-BOSTON-Data-in-Oral-Presentation-at-the-American-Society-of-Clinical-Oncology-2020-Virtual-Scientific-Program.html
http://www.pmlive.com/pharma_news/in_virtual_meeting,_chmp_backs_sanofis_myeloma_drug_sarclisa_1330202
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212958
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212825
http://www.pharmafile.com/news/535716/genmabs-darzalex-secures-chmp-recommendation-europe-front-line-multiple-myeloma
https://www.fiercepharma.com/pharma/ash-j-j-s-darzalex-cuts-death-risk-by-40-new-myeloma-patients
https://www.moneycontrol.com/news/business/dr-reddys-launches-cancer-treatment-injection-in-us-4699381.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208460
https://endpts.com/darzalex-from-jj-genmab-scores-fda-approval-in-frontline-multiple-myeloma-use-as-sanofi-rival-looms/
http://www.pharmatimes.com/news/xospata_leads_latest_chmp_recommendations_1302120
Market Place
Share 
